|
Characteristics
|
Global cohort (41 cases)
|
Discovery cohort (30 cases)
|
Validation cohort (11 cases)
|
p-value
|
|---|
|
Male sex, n (%)
|
28 (68.3)
|
15 (53.6)
|
11 (100)
|
0.003
|
|
Age, (mean ± SD), years
|
55 ± 12.7
|
53.9 ± 13.2
|
58 ± 11.1
|
0.324
|
|
IPMD, (mean ± SD), months
|
24.3 ± 26.4
|
25.3 ± 29.2
|
21.1 ± 13.4
|
0.523
|
|
Melanoma type, n (%)
|
|
NM
|
12 (29.3)
|
8 (26.7)
|
4 (36.4)
|
0.828
|
|
SSM
|
28 (68.3)
|
21 (70)
|
7 (63.6)
|
0.993
|
|
LMM
|
1 (2.4)
|
1 (3.3)
|
0 (0)
|
1.000
|
|
Melanoma site, n (%)
|
|
A. Primitive
|
|
Head
|
2 (4.9)
|
2 (6.7)
|
0 (0)
|
1.000
|
|
Neck
|
3 (7.3)
|
2 (6.7)
|
1 (9.1)
|
1.000
|
|
Trunk
|
19 (46.3)
|
13 (43.3)
|
6 (54.5)
|
0.776
|
|
Upper limbs
|
3 (7.3)
|
2 (6.7)
|
1 (9.1)
|
1.000
|
|
Lower limbs
|
14 (34.1)
|
11 (36.7)
|
3 (27.3)
|
1.000
|
|
B. Metastasis
|
49 (100)
|
36 (73.5)
|
13 (26.5)
|
0.853
|
|
Lymph nodes
|
31 (64.6)
|
23 (63.9)
|
8 (66.7)
|
|
Visceral
|
18 (35.4)
|
13 (36.1)
|
5 (33.3)
|
|
Number of mitosis per smm (mean ± SD)
|
3.4 ± 3.1
|
4.1 ± 3.0
|
1.6 ± 2.5
|
0.003
|
|
Breslow thickness, (mean ± SD)
|
3.8 ± 2.4
|
4.0 ± 2.4
|
3.2 ± 1.4
|
0.566
|
|
Ulceration, n (%)
|
18 (43.9)
|
12 (40)
|
6 (54.5)
|
0.634
|
|
Initial T/N stage, n (%)
|
|
A. T stage
|
|
T1
|
2 (4.9)
|
2 (6.7)
|
0
|
1.000
|
|
T2
|
7 (17.1)
|
5 (16.7)
|
2 (18.2)
|
1.000
|
|
T3
|
19 (46.3)
|
13 (43.3)
|
6 (54.5)
|
0.776
|
|
T4
|
13 (31.7)
|
10 (33.3)
|
3 (27.3)
|
1.000
|
|
B. N stage
|
|
N0
|
8 (19.5)
|
6 (20.0)
|
2 (18.2)
|
1.000
|
|
N1
|
16 (39.0)
|
11 (36.7)
|
5 (45.4)
|
0.723
|
|
N2
|
13 (31.7)
|
9 (30.0)
|
4 (36.4)
|
1.000
|
|
N3
|
4 (9.8)
|
4 (13.3)
|
0
|
0.559
|
- Significant p-values are indicated in italics
- IPMD interval progression of metastatic disease, LMM lentigo maligna melanoma, NM nodular melanoma, SD standard deviation, SSM superficial spreading melanoma
